Stockscreener 앱 받기
3.74
1.58%
-0.06
전일 마감가:
$3.80
열려 있는:
$3.8
하루 거래량:
540.62K
Relative Volume:
0.49
시가총액:
$274.27M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-1.1437
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
-13.23%
1개월 성능:
-16.89%
6개월 성능:
+516.86%
1년 성능:
+883.95%
1일 변동 폭
$3.66
$3.80
1주일 범위
$3.66
$4.4499
52주 변동 폭
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
3.01 | 4.25B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.93 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
3.86 | 370.02M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
8.28 | 332.44M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.64 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-22 | 개시 | Jefferies | Buy |
| 2025-11-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Bull Run: Is Relmada Therapeutics Inc in accumulation or distribution phase2025 Growth vs Value & Detailed Earnings Play Strategies - baoquankhu1.vn
Relmada’s New Phase 3 Bladder Cancer Trial Adds a Fresh Catalyst to Its Pipeline - TipRanks
FDA endorses Relmada’s registrational strategy for bladder cancer therapy - Indian Pharma Post
Is Relmada Therapeutics Inc stock affected by interest rate hikesWeekly Trend Summary & High Win Rate Trade Tips - Bộ Nội Vụ
Relmada’s BOOST phase 3 bladder cancer trial sets up a new catalyst for RLMD investors - MSN
Relmada receives FDA feedback for bladder cancer therapy trials By Investing.com - Investing.com Nigeria
Will Relmada Therapeutics Inc. (4E2) stock outperform energy sector in 2025Footwear buying guidance for all day wear during busy schedules focuses on foot fatigue reduction, making it helpful for judging overall value. - Улправда
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - Investing News Network
Relmada Therapeutics (RLMD) Advances NDV-01 with FDA Guidance - GuruFocus
Relmada gets FDA alignment on NDV-01 bladder cancer trial designs - StreetInsider
FDA backs new bladder cancer studies for patients with few options left - Stock Titan
Will Relmada Therapeutics Inc. stock benefit from infrastructure spendingForecast Cut & Low Risk High Reward Ideas - Улправда
How supply chain issues affect Relmada Therapeutics Inc. stockBuy Signal & Weekly Momentum Stock Picks - Улправда
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Corient Private Wealth LLC Invests $120,000 in Relmada Therapeutics, Inc. $RLMD - Defense World
Small Cap Biotech In 2025: Winning Pivots And Zombie Killers - Citeline News & Insights
Relmada’s BOOST Phase 3 Bladder Cancer Trial Sets Up a New Catalyst for RLMD Investors - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update - Defense World
Jefferies Financial Group Begins Coverage on Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of Relmada Therapeutics (RLMD) with Buy Recommendation - Nasdaq
Relmada Therapeutics (RLMD) Initiates Coverage with Buy Rating | RLMD Stock News - GuruFocus
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Treasury Yields: Is NEHC stock recession proof2025 Trading Recap & Weekly Stock Breakout Alerts - moha.gov.vn
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot - Investing.com Nigeria
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot By Investing.com - Investing.com South Africa
Jefferies Starts Relmada Therapeutics Inc (RLMD) at Buy - StreetInsider
Inflation Data: Will Las Vegas Sands Corp stock outperform value peersPortfolio Return Summary & Real-Time Market Sentiment Reports - moha.gov.vn
Is Relmada Therapeutics Inc. stock supported by strong cash flowsPortfolio Growth Summary & Entry Point Confirmation Alerts - Улправда
Why Relmada Therapeutics Inc. stock remains undervalued2025 Buyback Activity & Real-Time Buy Zone Alerts - Улправда
Momentum Shift: Why Relmada Therapeutics Inc. (4E2) stock benefits from AI revolution2025 Performance Recap & Low Risk Growth Stock Ideas - Улправда
Recap Report: Is Relmada Therapeutics Inc. stock supported by strong cash flowsBond Market & AI Enhanced Trading Alerts - Улправда
How Relmada Therapeutics Inc. (4E2) stock moves in volatile trading sessions2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
Is Relmada Therapeutics Inc. stock supported by innovation pipeline2025 Market Trends & Reliable Intraday Trade Alerts - Улправда
Have you been able to find a good deal on Relmada Therapeutics Inc’s shares? - uspostnews.com
RelmadaA New Contender To Watch In Bladder Cancer Drug Development? - RTTNews
Maged Shenouda Increases Stake in Relmada Therapeutics Inc (RLMD) - GuruFocus
Relmada Therapeutics (NASDAQ:RLMD) CFO Buys $48,059.80 in Stock - MarketBeat
Relmada Therapeutics updates executive contracts and increases salaries By Investing.com - Investing.com Australia
Relmada Therapeutics Amends Executive Employment Agreements - TipRanks
Relmada Therapeutics updates executive contracts and increases salaries - Investing.com
What analysts say about Relmada Therapeutics Inc stockMarket Insider Reports & Exceptional Profit Growth Tips - earlytimes.in
Aug Drivers: Can Relmada Therapeutics Inc stock outperform in 2025 bull marketAnalyst Upgrade & Safe Entry Trade Reports - moha.gov.vn
Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Taking on analysts’ expectations and winning: Relmada Therapeutics Inc (RLMD) - setenews.com
Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20 - Nasdaq
Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser
Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Relmada Therapeutics Inc 주식 (RLMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
4.73%
0.92%
자본화:
|
볼륨(24시간):